Ratings TerrAscend Corp.

Equities

TSND

CA88105E1088

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
2.29 ^CAD	-6.91%		-5.76%	+4.09%

May. 09	Transcript : TerrAscend Corp., Q1 2024 Earnings Call, May 09, 2024
May. 09	TerrAscend Brief: Q1 Net Revenue of US$80.6 million, an increase of 16.1% year-over-year; Cash Flow from operations of $13.3 million and Free Cash Flow of $10.5 million in the quarter	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

Low profitability weakens the company.
The company is in debt and has limited leeway for investment
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TERRASCEND CORP.	+4.09%	527M		-
GREEN THUMB INDUSTRIES INC.	+16.68%	3.07B		D+
VERANO HOLDINGS CORP.	+12.07%	1.77B		-
GLASS HOUSE BRANDS INC.	+100.63%	671M		-
HIGH TIDE INC.	+53.52%	174M		-
MARIMED INC.	-12.66%	94.91M		-
GOLD FLORA CORPORATION	+43.75%	63.28M	-	C
NOVA CANNABIS INC.	+33.71%	57.02M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes